FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W301227854> ?p ?o ?g. }

• W301227854 endingPage "30" @default.
• W301227854 startingPage "703" @default.
• W301227854 abstract "Hypoxia occurs to a variable extent in a vast majority of rodent and human solid tumors. It results from an inadequate and disorganized tumor vasculature, and hence an impaired oxygen delivery. A probe for the non-invasive detection of tumor hypoxia could find important utility in the selection of patients for therapy with bioreductive agents, anti-angiogenic/anti-vascular therapies and hypoxia-targeted gene therapy. In addition, tumor hypoxia has been shown to predict for treatment outcome following radio- or chemotherapy in human cancers, the underlying mechanism for which may involve hypoxia driving genetic instability and resulting tumor progression. Beyond oncology, utility can also be envisaged in stroke, ischemic heart disease, peripheral vascular disease, arthritis and other disorders. Design, validation, preclinical development and current status of a fluorinated 2-nitroimidazole, N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-l-imidazolyl) acetamide (SR 4554, CRC 94/17), which has been rationally designed for the measurement of tumor hypoxia by magnetic resonance spectroscopy (MRS) and imaging (MRI), are reviewed. Application in positron emission tomography (PET) detection is also proposed. Design goals were: (i) a nitro group with appropriate redox potential for selective reduction and binding in hypoxic tumor cells; (ii) hydrophilic/hydrogen bonding character in the side chain to limit nervous tissue penetration and prevent neurotoxicity; and (iii) three equivalent fluorine atoms to enhance MRS/MRI detection, located in a metabolically stable position. Reduction of SR 4554 by mouse liver microsomes was dependent on oxygen content, with a half-maximal inhibition at 0.48 +/- 0.06%. SR 4554 underwent nitroreduction by hypoxic but not oxic tumor cells in vitro and electron energy loss spectroscopic analysis showed selective retention in the hypoxic regions of multicellular tumor spheroids. Pharmacokinetic design goals were met. In particular, low brain tissue concentrations were seen in contrast to excellent tumor levels, as measured by high performance liquid chromatography. The extent of this restricted entry to brain tumor was surprising given the overall octanol/water partition coefficient and was attributed to the hydrophilic/hydrogen bonding character of the side chain. Quantitative MRS was used to assess the retention of 19F signal in murine tumors and human tumor xenografts. The 19F retention index (FRI; ratio of 19F signal levels at 6 h relative to that at 45 min) ranged from 0.5 to 1.0 and 0.2 to 0.9 for murine tumors and human xenografts respectively. The correlation between SR 4554 retention and pO2 was not a linear one, but when FRI was > 0.5, the % pO2 < or = 5 mmHg was always > 60%, indicating that high FRI was associated with low levels of oxygenation. Finally, whole body 19F-MRI in mice demonstrated that SR 4554 and related metabolites localized mainly in tumor, liver and bladder regions. A selective MRS signal was readily detectable in tumors at doses at least 7-fold lower than those likely to cause toxicity in mice. We conclude that proof of principle is established for the use of SR 4554 as a non-invasive MRS/MRI probe for the detection of tumor hypoxia. Based on these promising studies, SR 4554 has been selected for clinical development." @default.
• W301227854 created "2016-06-24" @default.
• W301227854 creator A5003965204 @default.
• W301227854 creator A5022232064 @default.
• W301227854 creator A5054775841 @default.
• W301227854 creator A5056342025 @default.
• W301227854 date "1998-09-01" @default.
• W301227854 modified "2023-10-17" @default.
• W301227854 title "Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography." @default.
• W301227854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9755726" @default.
• W301227854 hasPublicationYear "1998" @default.
• W301227854 type Work @default.
• W301227854 sameAs 301227854 @default.
• W301227854 citedByCount "16" @default.
• W301227854 crossrefType "journal-article" @default.
• W301227854 hasAuthorship W301227854A5003965204 @default.
• W301227854 hasAuthorship W301227854A5022232064 @default.
• W301227854 hasAuthorship W301227854A5054775841 @default.
• W301227854 hasAuthorship W301227854A5056342025 @default.
• W301227854 hasConcept C126322002 @default.
• W301227854 hasConcept C142724271 @default.
• W301227854 hasConcept C178790620 @default.
• W301227854 hasConcept C185592680 @default.
• W301227854 hasConcept C2776730177 @default.
• W301227854 hasConcept C2779081379 @default.
• W301227854 hasConcept C2779130545 @default.
• W301227854 hasConcept C2779491297 @default.
• W301227854 hasConcept C29730261 @default.
• W301227854 hasConcept C502942594 @default.
• W301227854 hasConcept C509974204 @default.
• W301227854 hasConcept C540031477 @default.
• W301227854 hasConcept C71924100 @default.
• W301227854 hasConcept C7836513 @default.
• W301227854 hasConcept C98274493 @default.
• W301227854 hasConceptScore W301227854C126322002 @default.
• W301227854 hasConceptScore W301227854C142724271 @default.
• W301227854 hasConceptScore W301227854C178790620 @default.
• W301227854 hasConceptScore W301227854C185592680 @default.
• W301227854 hasConceptScore W301227854C2776730177 @default.
• W301227854 hasConceptScore W301227854C2779081379 @default.
• W301227854 hasConceptScore W301227854C2779130545 @default.
• W301227854 hasConceptScore W301227854C2779491297 @default.
• W301227854 hasConceptScore W301227854C29730261 @default.
• W301227854 hasConceptScore W301227854C502942594 @default.
• W301227854 hasConceptScore W301227854C509974204 @default.
• W301227854 hasConceptScore W301227854C540031477 @default.
• W301227854 hasConceptScore W301227854C71924100 @default.
• W301227854 hasConceptScore W301227854C7836513 @default.
• W301227854 hasConceptScore W301227854C98274493 @default.
• W301227854 hasIssue "6" @default.
• W301227854 hasLocation W3012278541 @default.
• W301227854 hasOpenAccess W301227854 @default.
• W301227854 hasPrimaryLocation W3012278541 @default.
• W301227854 hasRelatedWork W2083083625 @default.
• W301227854 hasRelatedWork W2180963463 @default.
• W301227854 hasRelatedWork W2186721995 @default.
• W301227854 hasRelatedWork W2257188943 @default.
• W301227854 hasRelatedWork W2296827950 @default.
• W301227854 hasRelatedWork W2472108810 @default.
• W301227854 hasRelatedWork W2899084033 @default.
• W301227854 hasRelatedWork W2951783142 @default.
• W301227854 hasRelatedWork W301227854 @default.
• W301227854 hasRelatedWork W3215216432 @default.
• W301227854 hasVolume "13" @default.
• W301227854 isParatext "false" @default.
• W301227854 isRetracted "false" @default.
• W301227854 magId "301227854" @default.
• W301227854 workType "article" @default.